Indian clinical practice consensus guidelines for the management of nasopharyngeal cancer: Update 2022

Patients with early-stage nasopharyngeal cancer are treated with definitive radiotherapy alone, including both sides of the neck and retropharyngeal nodes. For patients with locoregionally advanced nasopharyngeal cancer, the recommendation is concurrent chemoradiotherapy with additional chemotherapy...

Full description

Saved in:
Bibliographic Details
Published inCancer research, statistics, and treatment (Online) Vol. 7; no. Suppl 1; pp. S27 - S30
Main Authors Gairola, Munish, Prabhash, Kumar, Babu, K Govind, Chaturvedi, Pankaj, Kuriakose, Moni, Birur, Praveen, Anand, Anil K., Kaushal, Ashish, Mahajan, Abhishek, Syiemlieh, Judita, Singhal, Manish, Ramachandra, Prakash, Goyal, Sumit, John, Subashini, Nayyar, Rohit, Patil, Vijay M., Rao, Vishal, Noronha, Vanita, Roshan, Vikas, Rath, G.K.
Format Journal Article
LanguageEnglish
Published 01.01.2024
Online AccessGet full text

Cover

More Information
Summary:Patients with early-stage nasopharyngeal cancer are treated with definitive radiotherapy alone, including both sides of the neck and retropharyngeal nodes. For patients with locoregionally advanced nasopharyngeal cancer, the recommendation is concurrent chemoradiotherapy with additional chemotherapy (either before or after chemoradiotherapy). Adding targeted therapies like nimotuzumab to concurrent chemoradiation in the management of nasopharyngeal cancer has been shown to improve overall survival with excellent safety and tolerability.
ISSN:2590-3233
2590-3225
DOI:10.4103/crst.crst_123_23